Ocimum collaborates with New York-based Hospital

By siliconindia   |   Monday, 07 July 2003, 19:30 IST
Printer Print Email Email
HYDERABAD: Delaware-based Ocimum Biosolutions today announced a collaboration with the New York-based Hospital of Joint Diseases (HJD) to analyze HJD’s Musculoskeletal Diseases Data. Ocimum will use its microarray analysis tool--Genowiz--to analyze the data. Genowiz is a gene expression analysis and tracking tool that enables researchers to analyze microarray data in an intuitive and comprehensive bio-environment. It includes novel quantification matrices and algorithms that facilitate expression pattern analysis and metabolic pathway insights. Ocimum’s CEO Anuradha Acharya commented, "This partnership will enhance our capabilities in analyzing expression data and fine tuning our product, Genowiz. We are also participating in cutting edge research with one of the world’s foremost research groups in rheumatoid arthritis." HJD’s Dr. Ashok Amin, Director of the Rheumatology Research Laboratory and Laboratory for Functional and Pharmacogenomics, said, "Data analysis (storage, integration, annotation, statistical analysis and clustering) is a challenging task in this uncharted area of translational genomics. Ocimum Biosolutions has the tools to tackle the complexity. Dr. Steven Abramson (Chairman, Department of Rheumatology at HJD and New York University (NYU) Medical Center) and I are committed to exploring the hope and metamorphosis that pharmacogenomics brings into molecular medicine." Ocimum Biosolutions is a life sciences contract R&D Company with its operations at Costa Mesa, California and Hyderabad, India.

siliconindia